Likes Subject
Thinking next week run up . WVMA is Wolfofwitz 06/02/23 3:15 PM
buddy, the tale is in the price.. this pitacorp 05/31/23 7:36 PM
VTGN: All of my usual JOKING aside, see below:
Invest-in-America 05/31/23 11:23 AM
VTGN: Ooooops!!! (This iHub post is Rated "PG-40"[
Invest-in-America 05/31/23 10:10 AM
VTGN: And here we GOOOOOOOOOO!!!!!! To dah MOON ,
Invest-in-America 05/31/23 9:50 AM
Vistagen to Present Fasedienol (PH94B) Safety and Exploratory tw0122 05/31/23 5:31 AM
8:30AM TheFinalCD 05/30/23 7:28 PM
Getting volume here Golden Cross 04/06/23 12:34 PM
sincerely ? I thought a much stronger reaction... corvatsch 04/06/23 10:15 AM surf1944 04/06/23 9:15 AM
you are probably correct.. i should have as pitacorp 03/26/23 1:37 PM
Yep.. not a hold. I got out. kzivann 03/23/23 9:54 AM
should have dumpd then.. nothing more than a pitacorp 03/23/23 9:34 AM
Premarket news. Volume and PPS up. kzivann 03/22/23 8:53 AM
if this just keeps trading sideways, i am pitacorp 03/04/23 5:38 AM
yes,.....we should all be doing the same then... pitacorp 02/25/23 4:16 PM
Break of my leg lol INFINITI 02/25/23 2:38 PM
what break? and what would be driving that break? pitacorp 02/25/23 1:04 PM
Waiting patiently for that Break $$$$ INFINITI 02/22/23 6:44 AM
we did exactly fly last monday, but I pitacorp 02/19/23 10:55 PM
i hope you are correct with this way pitacorp 02/17/23 9:21 PM
I decided to buy in. News has to purdue 02/17/23 12:46 PM
Load up $$$$ INFINITI 02/13/23 10:40 AM
agreed........... pitacorp 02/11/23 9:42 PM
Monday we fly $$$$$ INFINITI 02/11/23 9:22 PM
VTGN...................... glenn1919 02/10/23 4:08 PM
I’m in $$$$ INFINITI 02/10/23 1:39 PM
Such a disappointing Company! Traderboy1966 02/08/23 4:16 PM
not the way we are going these days pitacorp 02/08/23 4:07 PM
We will hit it, maybe within the next kwaza 02/06/23 9:50 AM
VTGN............................ glenn1919 02/06/23 9:47 AM
I am holding for a dollar and I purdue 02/05/23 8:32 PM
7 days later .32 LFG get paid! selling MatrixMoney 02/05/23 6:45 PM
VTGN looking good so far kwaza 02/03/23 8:43 PM
Added full position .22 this is going up MatrixMoney 01/29/23 3:49 PM
Thanks. I am surprised VTGN isn't getting more purdue 01/16/23 8:29 AM
hopefully VGTN makes it big...I'm sorry for your loss... dealerschool2006 01/15/23 5:54 PM
VTGN has several products in the pipeline. I purdue 01/15/23 8:47 AM
My buddy sent me a Pm about VTGN dealerschool2006 01/14/23 3:15 AM
Yes and the news looks good to me. FORDGT 01/09/23 11:41 AM
Anybody watching vtgn?
purdue 01/09/23 11:16 AM
In December, 2022 the (VTGN) VistaGen Therapeutics, Inc. FORDGT 12/28/22 2:17 PM
Conference went well. And recent news is FORDGT 12/22/22 11:43 AM
On December 20, 2022, Vistagen Therapeutics, Inc. (the INFINITI 12/21/22 9:29 AM
Vistagen to Acquire Pherin Pharmaceuticals Source: Business Wire Vistagen’s acq INFINITI 12/21/22 8:59 AM
There should be a conference today. Here is FORDGT 12/15/22 8:15 AM
Yes I do believe so. But I don't FORDGT 12/07/22 1:32 PM
Is there any r/s on the table ? TheHungryHippo 12/07/22 1:15 PM
Management is getting the job done here and FORDGT 12/07/22 12:58 PM
Just bought in today I like what I'm seeing Amrsto1000 12/06/22 7:48 PM
Likes Subject

06/02/23 3:15 PM
05/31/23 7:36 PM
05/31/23 11:23 AM
05/31/23 10:10 AM
05/31/23 9:50 AM
Golden Cross
04/06/23 12:34 PM
03/23/23 9:54 AM
03/22/23 8:53 AM
03/04/23 5:38 AM
02/25/23 2:38 PM
02/22/23 6:44 AM
02/19/23 10:55 PM
02/17/23 9:21 PM
02/17/23 12:46 PM
02/13/23 10:40 AM
02/11/23 9:42 PM
02/11/23 9:22 PM
02/10/23 1:39 PM
02/08/23 4:16 PM
02/08/23 4:07 PM
02/06/23 9:50 AM
02/05/23 8:32 PM
02/05/23 6:45 PM
02/03/23 8:43 PM
01/29/23 3:49 PM
01/14/23 3:15 AM
01/09/23 11:41 AM
01/09/23 11:16 AM
12/22/22 11:43 AM
12/07/22 1:32 PM
12/07/22 1:15 PM
12/06/22 7:48 PM

VistaGen Therapeutics Inc (VTGN)

Posts (Today)
Posts (Total)
VistaGen Therapeutics, Inc.
343 Allerton Avenue
South San Francisco, CA 94080

VistaGen Therapeutics, Inc. (NASDAQ: VTGN) is a clinical-stage biopharmaceutical company committed to developing and commercializing new generation medications that go beyond the current standard of care for anxiety, depression and other central nervous system (CNS) disorders. Our CNS portfolio includes three differentiated drug candidates, PH94B, PH10 and AV-101, each with a novel mechanism of action, an exceptional safety profile in all studies to date, and therapeutic potential for multiple indications.

Company WebsiteVistaGen Therapeutics, Inc. (VTGN)                                                                                               Press ReleasesPress Releases :: VistaGen Therapeutics, Inc. (VTGN)

FinancialsAll SEC Filings :: VistaGen Therapeutics, Inc. (VTGN)                                                                                 Leadership TeamLeadership :: VistaGen Therapeutics, Inc. (VTGN)

Current Stock PriceQuote :: VistaGen Therapeutics, Inc. (VTGN)                                                                               



Our CNS pipeline includes three differentiated new generation CNS drug candidates with potential to go beyond the current standard of care for anxiety, depression and other CNS disorders. Each of our drug candidates, PH94B, PH10 and AV-101, has a novel mechanism of action, an exceptional safety profile in all studies to date, and therapeutic potential for multiple indications in large mental health and neurology markets.

PH94B Neuroactive Nasal Spray

PH94B is an innovative investigational synthetic neuroactive pherine nasal spray with potential to treat multiple anxiety disorders without the side effects and safety concerns associated with benzodiazepines. PH94B’s rapid-onset mechanism of action is fundamentally different from benzodiazepines and all other FDA-approved anti-anxiety medications. Developed from proprietary compounds called pherines and administered at non-systemic microgram doses as an odorless nasal spray, PH94B binds to nasal chemosensory receptors which activate neural circuits in the limbic amygdala that suppress fear and anxiety. Following a highly statistically significant (p=0.002) Phase 2 study of PH94B in adults with social anxiety disorder (SAD), and a successful meeting with the U.S. Food and Drug Administration (FDA), we are currently preparing for pivotal Phase 3 development of PH94B for the acute treatment of anxiety in adults with SAD.

The FDA has granted Fast Track designation for development of PH94B for SAD, the first such designation ever granted by the FDA for a SAD drug candidate. In a manner analogous to a rescue inhaler used before an asthma attack, PH94B has potential to be used by a person with SAD before an anxiety-provoking stressor.

Based on the results of Phase 2 studies, PH94B has the potential to be the first FDA-approved acute (on-demand) treatment of anxiety for millions who suffer from SAD. In addition, PH94B has potential in postpartum anxiety, preoperative anxiety, PTSD, panic disorder, and generalized anxiety disorder.

PH10 Neuroactive Nasal Spray

PH10 is a synthetic investigational neuroactive pherine nasal spray with a novel, rapid-onset mechanism of action that is fundamentally different from all current treatments for depression. Developed from proprietary compounds called pherines and administered at microgram doses as an odorless nasal spray, PH10 binds to nasal chemosensory receptors which activate neural circuits in the brain that produce antidepressant effects. Specifically, a microgram level dose of PH10 (6.4 mcg) engages specific nasal chemosensory neurons (NCNs). NCNs activate olfactory bulb neurons (OBNs) on the base of the brain. OBNs send neural connections to neurons in the central limbic amygdala, the brain center where mood is regulated. Neurons in the limbic amygdala stimulate release of excitatory neurotransmitters (glutamate, norepinephrine) resulting in rapid-onset antidepressant effects. Systemic uptake and distribution are not required to produce rapid-onset antidepressant effects. In a small exploratory randomized, double-blind, placebo-controlled Phase 2A clinical study in major depressive disorder (MDD), at a 6.4 mcg dose, rapid-onset antidepressant effects were observed and sustained for 8 weeks (p=0.022), without psychological side effects or safety concerns associated with ketamine-based therapy.

AV-101, an Oral NMDAR Glycine Site Antagonist

AV-101 (4-Cl-KYN) belongs to a new generation of investigational medicines in neuropsychiatry and neurology known as NMDA (N-methyl-D-aspartate) glutamate receptor modulators. The NMDA receptor is a pivotal receptor in the brain and abnormal NMDA function is associated with multiple CNS diseases and disorders, including MDD, epilepsy, levodopa-induced dyskinesia, neuropathic pain and many others. AV-101 is an oral prodrug of 7-chlorokynurenic acid (7-Cl-KYNA), which binds uniquely at the glycine site of the NMDA receptor and has potential to be a new treatment for multiple CNS indications involving NMDA receptors, each with high unmet need.

Recent discoveries from successful AV-101 preclinical studies demonstrate a multi-fold concentration increase in the brain of AV-101 prodrug, and, more importantly, of 7-Cl-KYNA, AV-101's active metabolite, when AV-101 is administered adjunctively with probenecid, a safe and well-known oral anion transport inhibitor used to treat gout. This data suggest that it may be possible to increase therapeutic concentrations and duration of 7-Cl-KYNA in the brain, and thus increase NMDAR antagonism in patients when AV-101 and probenecid are combined.

VistaGen Investor Contact
Mark McPartland
VistaGen Therapeutics
Phone: (650) 577-3606

Most Liked Posts
(Last 30 Days)
New Post